These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12737421)

  • 41. FDA perspectives on supplement use by patients on antithrombotic therapy.
    Kim MJ
    Thromb Res; 2005; 117(1-2):197-200; discussion 201-7. PubMed ID: 16188297
    [No Abstract]   [Full Text] [Related]  

  • 42. Importing prescription drugs: risky business.
    Hassel L; Arzuaga P
    Empl Benefits J; 2003 Dec; 28(4):83-6. PubMed ID: 14712740
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Trends in the utilization of internet for facilitating transparent and more active stakeholder participation in the Codex process in several countries].
    Toyofuku H; Kubota K; Morikawa K
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2006; (124):30-7. PubMed ID: 17405519
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Price regulation and generic competition in the pharmaceutical market.
    Dalen DM; Strøm S; Haabeth T
    Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [First drafts of the Environmental Health Criteria (EHC) circulated for comments by IPCS in 1999.4-2000.3].
    Ohtake C
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2000; (118):129-30. PubMed ID: 11534112
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biosimilar therapeutic agents: issues with bioequivalence and immunogenicity.
    Schellekens H
    Eur J Clin Invest; 2004 Dec; 34(12):797-9. PubMed ID: 15606720
    [No Abstract]   [Full Text] [Related]  

  • 47. [The draft Resolution on medications exclusively pharmaceutical].
    Pharm Weekbl; 1967 Jun; 102(24):549-83. PubMed ID: 6077696
    [No Abstract]   [Full Text] [Related]  

  • 48. The US Food and Drug Administration and probiotics: regulatory categorization.
    Degnan FH
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S133-6; discussion S144-51. PubMed ID: 18181719
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The patent legislation in India fails the HIV/AIDS work].
    Holen Ø
    Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2666-7. PubMed ID: 16215618
    [No Abstract]   [Full Text] [Related]  

  • 50. Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. Interim final rule with request for comments.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2009 Apr; 74(64):15595-625. PubMed ID: 19507319
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FDA perspectives on supplement use by patients on antithrombotic therapy: dietary supplement regulatory overview.
    Woo JJ
    Thromb Res; 2005; 117(1-2):193-6; discussion 201-7. PubMed ID: 16253311
    [No Abstract]   [Full Text] [Related]  

  • 52. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance.
    Godman B; Wettermark B; Hoffmann M; Andersson K; Haycox A; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):65-83. PubMed ID: 19371180
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Democrats prioritize pricing, generics and drug safety.
    Fox JL
    Nat Biotechnol; 2007 Feb; 25(2):150-1. PubMed ID: 17287735
    [No Abstract]   [Full Text] [Related]  

  • 54. [The "evil" pharmacists].
    Heinzl S
    Med Monatsschr Pharm; 2005 Jun; 28(6):185. PubMed ID: 15960419
    [No Abstract]   [Full Text] [Related]  

  • 55. Pediatric priorities: legislative and regulatory initiatives to expand research on the use of medicines in pediatric patients.
    Labson MS
    J Health Care Law Policy; 2002; 6(1):34-72. PubMed ID: 15017951
    [No Abstract]   [Full Text] [Related]  

  • 56. Amendments to the Canadian Patent Act to address drug access: is help on the way?
    Penner MD; Narayanan P
    Food Drug Law J; 2005; 60(3):459-70. PubMed ID: 16304751
    [No Abstract]   [Full Text] [Related]  

  • 57. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Who sells drugs in rural Zaire?
    Ntambwe M; Luwombo I; Djurna O
    World Health Forum; 1994; 15(1):62-3. PubMed ID: 8141982
    [No Abstract]   [Full Text] [Related]  

  • 59. [First drafts of the environmental health criteria (EHC) circulated for comments by IPCS in 1997.4-1998.3].
    Ohtake C
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1998; (116):144-8. PubMed ID: 10097525
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Testing new drugs: the responsibility of government.
    Scowen E
    J R Coll Physicians Lond; 1977 Apr; 11(3):234-8. PubMed ID: 853462
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.